Details for Patent: 10,941,142

Which drugs does patent 10,941,142 protect, and when does it expire?

Patent 10,941,142 protects TURALIO and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 10,941,142

Title:	Formulations of a compound modulating kinases
Abstract:	Provided are compositions comprising Compound I having the following structure: ##STR00001## or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.
Inventor(s):	Ibrahim; Prabha N. (Mountain View, CA), Rezaei; Hamid (Berkeley, CA), Visor; Gary Conard (Castro Valley, CA), Kamo; Tomoari (Tokyo, JP), Yamakose; Hiroshi (Tokyo, JP)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	16/510,764
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Process;

Drugs Protected by US Patent 10,941,142

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	No			Y
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		DISCN	Yes	No			Y

International Family Members for US Patent 10,941,142

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018307910
Brazil	112019028235
Canada	3070505
China	110944670
European Patent Office	3658189
Japan	2020528884